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 3 
To the Editor,  4 
I read the recent study by Connelly et al. with interest [1]. The high short-term failure rate of 5 
metal-on-metal hip arthroplasty (MoMHA) has led to almost all patients requiring regular 6 
surveillance. However surveillance regimens are variable and do not reflect the best evidence 7 
[2]. Furthermore there are numerous important questions which must be answered so we can 8 
modify follow-up protocols accordingly and make them clinically and cost-effective [2-4]. 9 
The authors of the present study had access to a large prospective multicenter database, 10 
which included patients with the recalled metal-on-metal Articular Surface Replacement 11 
(ASR) hip system. This database provides a useful resource to answer some of the important 12 
clinical questions around the investigation and management of MoMHA patients with this 13 
particular device, and the authors have subsequently written a number of papers using this 14 
dataset. However it is important to keep in mind that the questions posed must be clinically 15 
relevant. I would argue in this particular study of ASR XL implants by Connelly et al. [1] the 16 
research question is not clinically relevant, as is the case for their other recent paper on ASR 17 
hip resurfacings [5]. 18 
 19 
The ASR XL system has the highest revision rate of any total hip arthroplasty device that I 20 
am aware of over recent years. Langton et al. reported it to be 49% at 6 years back in 2011 21 
[6]. Current registry data from Australia and the United Kingdom consistently report 10 year 22 
revision rates for the ASR XL system of between 44% and 46% with the ASR hip resurfacing 23 
also performing very poorly [7, 8]. Both these registries have shown a gradual and steady 24 
increase in revision rates over the 10 years for ASR devices, rather than an initial high short-25 
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term revision rate followed by a plateau. These observations are consistent with the patterns 26 
seen in 10 to 15 year outcomes for non-ASR hip resurfacings and non-ASR total hip 27 
arthroplasties, although these other devices have not failed at such a spectacular rate as the 28 
ASR [9-11]. 29 
 30 
Thankfully the ASR device was recalled by the manufacturer back in 2010 and is no longer 31 
implanted. However there has been substantial medico-legal implications with the device 32 
manufacturers paying billions of dollars in compensation to patients with failing ASR 33 
implants [12]. For these reasons it has been recommended since 2012 that all patients with 34 
ASR XL and ASR hip resurfacing implants require annual investigation, which should 35 
include cross-sectional imaging in all cases [13]. 36 
 37 
It is therefore unclear why the studies by Connelly et al. have investigated how to rationalize 38 
the use of MARS-MRI imaging in this group of patients with high risk withdrawn implants [1, 39 
5]. The main reason they state relates to the extra cost of these investigations, however I 40 
would propose that this can largely be ignored given the catastrophic failure of this implant 41 
design and the need to first protect our patients from future problems. Furthermore the 42 
authors claim that the algorithm they developed was “highly sensitive and specific”, and that 43 
it “outperformed existing national guidelines” [1]. From the data presented I would question 44 
these bold statements. Although the sensitivity presented for the devised algorithm was 86% 45 
for detecting adverse local tissue reaction (ALTR) on MARS-MRI for the ASR XL, this is 46 
simply not good enough given everything we know about ASR implants and the significant 47 
implications of missing ALTR in this high-risk population. I propose that most patients with 48 
these devices still in-situ would not consider these results from targeted cross-sectional 49 
imaging acceptable. 50 
 3 
 51 
The authors have used the area under the curve (AUC) to assess the discriminatory ability of 52 
their new algorithm (AUC of 50% = a non-discriminatory algorithm; AUC of 100% = 53 
algorithm with perfect discrimination). Whilst their new algorithm had the highest AUC of 54 
the other guidelines assessed, it was still only 63% [1]. This does not therefore represent a 55 
clinically useful algorithm, especially given the context of the clinical problem. Furthermore 56 
the confidence intervals for the AUC associated with the new algorithm actually overlap with 57 
those from the two other sets of guidelines assessed, therefore the authors cannot claim any 58 
superiority of their algorithm over existing guidance. Interestingly in both studies the authors 59 
have knowingly compared their algorithm in ASR patients to the non-ASR MoMHA 60 
guidance published by the MHRA, rather than using the ASR specific MHRA guidance, 61 
which exclusively recommends cross-sectional imaging in all cases. This therefore makes 62 
both the current study and their previous study unnecessary [1, 5]. 63 
 64 
In light of the high revision rate of ASR implants, the widely publicized manufacturer recall, 65 
the related medico-legal issues, coupled with the ever increasing revision rate in arthroplasty 66 
registries, I would urge clinicians reading these two articles by Connelly et al. to continue to 67 
follow-up patients with the ASR device on a regular basis. This follow-up must include 68 
regular cross-sectional imaging, given blood metal ions alone are not adequate in this patient 69 
population with Connelly et al. themselves reporting that blood metal ions only have a 70 
sensitivity of between 69%-75% for identifying ALTR on MARS-MRI [1]. Finally, care 71 
should be taken when embarking on future studies to ensure the research questions set are 72 
clinically relevant. 73 
 74 
 75 
 4 
References 76 
1. Connelly JW, Galea VP, Laaksonen I, Matuszak SJ, Madanat R, Muratoglu O, Malchau H. 77 
Indications for MARS-MRI in Patients Treated With Articular Surface Replacement XL 78 
Total Hip Arthroplasty. J Arthroplasty 2018; doi: 10.1016/j.arth.2018.04.021. 79 
2. Matharu GS, Mellon SJ, Murray DW, Pandit HG. Follow-Up of Metal-on-Metal Hip 80 
Arthroplasty Patients Is Currently Not Evidence Based or Cost Effective. J Arthroplasty. 81 
2015;30(8):1317-1323. 82 
3. Matharu GS, Judge A, Eskelinen A, Murray DW, Pandit HG. What is appropriate 83 
surveillance for metal-on-metal hip arthroplasty patients? A clinical update. Acta Orthop 84 
2018; 89 (1): 29-39. 85 
4. Matharu GS, Eskelinen A, Judge A, Pandit HG, Murray DW. Revision surgery of metal-86 
on-metal hip arthroplasties for adverse reactions to metal debris: A clinical update. Acta 87 
Orthop2018; 89 (3); 278-288. 88 
5. Connelly JW, Galea VP, Matuszak SJ, Madanat R, Muratoglu O, Malchau H. Indications 89 
for MARS-MRI in Patients Treated With Metal-on-Metal Hip Resurfacing Arthroplasty. J 90 
Arthroplasty 2018; 33(6): 1919-1925. 91 
6. Langton DJ, Jameson SS, Joyce TJ, Gandhi JN, Sidaginamale R, Mereddy P, Lord J, 92 
Nargol AV. Accelerating failure rate of the ASR total hip replacement. J Bone Joint Surg Br. 93 
2011;93(8):1011-1016. 94 
7. Australian Orthopaedic Association National Joint Replacement Registry. Hip, Knee & 95 
Shoulder Arthroplasty. Annual Report 2017. https://aoanjrr.sahmri.com/annual-reports-2017 96 
8. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. 14th 97 
Annual Report. 2017. 98 
http://www.njrreports.org.uk/Portals/0/PDFdownloads/NJR%2014th%20Annual%20Report99 
%202017.pdf 100 
 5 
9. Langton DJ, Sidaginamale RP, Avery P, Waller S, Tank G, Lord J, Joyce T, Cooke N, 101 
Logishetty R, Nargol AV. Retrospective cohort study of the performance of the Pinnacle 102 
metal on metal (MoM) total hip replacement: a single-centre investigation in combination 103 
with the findings of a national retrieval centre. BMJ Open. 2016;6(4):e007847. 104 
10. Matharu GS, Nandra R, Berryman F, Judge A, Pynsent PB, Dunlop DJ. Risk factors for 105 
failure of the 36 mm metal-on-metal Pinnacle total hip replacement system: a retrospective 106 
single-centre cohort study. Bone Joint J. 2017; 99-B(5): 592-600. 107 
11.  Matharu GS, Judge A, Murray DW, Pandit HG. Prevalence of and risk factors for hip 108 
resurfacing revision: a cohort study into the second decade after the operation. J Bone Joint 109 
Surg Am 2016; 98 (17): 1444-1452. 110 
12. https://www.nytimes.com/2013/11/20/business/johnson-johnson-to-offer-2-5-billion-hip-111 
device-settlement.html 112 
13. MHRA. Medical Device Alert: all metal-on-metal (MoM) hip replacements. 113 
MDA/2012/036. 2012. https://www.gov.uk/drug-device-alerts/medical-device-alert-metal-114 
on-metal-mom-hip-replacements-updated-advice-with-patient-follow-ups. 115 
